A new study finds that many tumors in tens of thousands squamous cell lung cancer patients have mutations that might be treated by drugs that are already being developed or could be easily developed, according to The New York Times.
Drugs could potentially be tailored to match the different genetic abnormalities found in each patient of the disease that kills about 50,000 people each year.
With the study comparing the infected cells to the normal healthy cells of 178 squamous cell lung cancer patients, it was found that over 60% of the tumors would be particularly vulnerable to new cancer drugs that are already available or being tested in other cancers.
“‘This is a disease where there are no targeted therapies,'” said Dr. Matthew Meyerson of the Dana-Farber Cancer Institute, referring to modern drugs that attack genetic abnormalities. “‘What we found will change the landscape for squamous cell carcinoma. I think it gives hope to patients.” Read the full details here:
“Lung cancer is unfortunately a lethal killer where all types and stages of cancer are sentenced to a very low survival rate,” said Steve Crandall, a top-rated medical malpractice attorney throughout Ohio and Kentucky. “Any treatment which may enhance survival rates is welcome news.”
If you have any questions regarding medical malpractice throughout Ohio and Kentucky, contact Steve Crandall. Steve is available to help answer your questions and guide you in determining your next steps.